Immunic Stock Performance
| IMUX Stock | USD 0.92 0.05 5.75% |
On a scale of 0 to 100, Immunic holds a performance score of 7. The company retains a Market Volatility (i.e., Beta) of 0.63, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, Immunic's returns are expected to increase less than the market. However, during the bear market, the loss of holding Immunic is expected to be smaller as well. Please check Immunic's maximum drawdown, as well as the relationship between the skewness and day typical price , to make a quick decision on whether Immunic's current trending patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Immunic are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Immunic showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:40 | Dividend Date 2019-04-15 | Last Split Date 2019-04-15 |
1 | Immunic Upgraded at Chardan Capital | 11/21/2025 |
2 | How Immunic Inc. stock performs in stagflation - 2025 Investor Takeaways Target Return Focused Picks - Newser | 12/03/2025 |
3 | William Blair Maintains Immunic With Buy Rating - | 12/16/2025 |
4 | Immunic Highlights 2025 Accomplishments and Upcoming Milestones | 01/07/2026 |
5 | Brokerages Set Immunic, Inc. PT at 7.40 | 01/12/2026 |
6 | Insider Traders Lose US42k As Immunic Drops | 01/30/2026 |
7 | Acquisition by Muehler Andreas of 598500 shares of Immunic at 0.7729 subject to Rule 16b-3 | 02/05/2026 |
8 | Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum | 02/10/2026 |
| Begin Period Cash Flow | 46.7 M | |
| Total Cashflows From Investing Activities | -264 K |
Immunic Relative Risk vs. Return Landscape
If you would invest 73.00 in Immunic on November 15, 2025 and sell it today you would earn a total of 18.00 from holding Immunic or generate 24.66% return on investment over 90 days. Immunic is currently generating 0.5021% in daily expected returns and assumes 5.4306% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of stocks are less volatile than Immunic, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunic Target Price Odds to finish over Current Price
The tendency of Immunic Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.92 | 90 days | 0.92 | near 1 |
Based on a normal probability distribution, the odds of Immunic to move above the current price in 90 days from now is near 1 (This Immunic probability density function shows the probability of Immunic Stock to fall within a particular range of prices over 90 days) .
Immunic Price Density |
| Price |
Predictive Modules for Immunic
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immunic. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Immunic's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Immunic Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Immunic is not an exception. The market had few large corrections towards the Immunic's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Immunic, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Immunic within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.38 | |
β | Beta against Dow Jones | 0.63 | |
σ | Overall volatility | 0.07 | |
Ir | Information ratio | 0.06 |
Immunic Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Immunic for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Immunic can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Immunic is way too risky over 90 days horizon | |
| Immunic has some characteristics of a very speculative penny stock | |
| Immunic appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (100.51 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunic currently holds about 72.77 M in cash with (84.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunic has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum |
Immunic Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Immunic Stock often depends not only on the future outlook of the current and potential Immunic's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immunic's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 100.2 M | |
| Cash And Short Term Investments | 35.7 M |
Immunic Fundamentals Growth
Immunic Stock prices reflect investors' perceptions of the future prospects and financial health of Immunic, and Immunic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunic Stock performance.
| Return On Equity | -3.98 | ||||
| Return On Asset | -1.25 | ||||
| Current Valuation | 54.95 M | ||||
| Shares Outstanding | 120.28 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 8.50 X | ||||
| EBITDA | (97.92 M) | ||||
| Net Income | (100.51 M) | ||||
| Cash And Equivalents | 72.77 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 1 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 0.11 X | ||||
| Cash Flow From Operations | (84.77 M) | ||||
| Earnings Per Share | (0.80) X | ||||
| Market Capitalization | 89.29 M | ||||
| Total Asset | 40.87 M | ||||
| Retained Earnings | (511.4 M) | ||||
| Working Capital | 17.16 M | ||||
| Current Asset | 32.33 M | ||||
| Current Liabilities | 4.73 M | ||||
About Immunic Performance
Evaluating Immunic's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Immunic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Immunic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -2.7 K | -2.8 K | |
| Return On Tangible Assets | (2.83) | (2.69) | |
| Return On Capital Employed | (6.03) | (5.73) | |
| Return On Assets | (2.83) | (2.69) | |
| Return On Equity | (6.27) | (5.96) |
Things to note about Immunic performance evaluation
Checking the ongoing alerts about Immunic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunic is way too risky over 90 days horizon | |
| Immunic has some characteristics of a very speculative penny stock | |
| Immunic appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (100.51 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunic currently holds about 72.77 M in cash with (84.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.85, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Immunic has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Immunic showcases Phase 2 data on vidofludimus calcium at ACTRIMS Forum |
- Analyzing Immunic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunic's stock is overvalued or undervalued compared to its peers.
- Examining Immunic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunic's stock. These opinions can provide insight into Immunic's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunic Stock Analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.